Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125
Open Access
- 17 August 2021
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology Reports
- Vol. 38, 100847
- https://doi.org/10.1016/j.gore.2021.100847
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Liquid biopsy: monitoring cancer-genetics in the bloodNature Reviews Clinical Oncology, 2013
- HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy AlgorithmBritish Journal of Cancer, 2011
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing dataGenome Research, 2010
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing dataNucleic Acids Research, 2010
- CA 125, PET alone, PET–CT, CT and MRI in diagnosing recurrent ovarian carcinoma: A systematic review and meta-analysisEuropean Journal of Radiology, 2009
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric studyAnnals of Oncology, 2006
- The UCSC Genome Browser Database: update 2006Nucleic Acids Research, 2006
- Risk of Epithelial Ovarian Cancer Recurrence in Patients With Rising Serum CA-125 Levels Within the Normal RangeJournal of Clinical Oncology, 2005
- Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group studyAnnals of Oncology, 1996